NO971487D0 - 5-HT1F-formidlet inhibering av neurogenisk hjernehinne-ekstravasjon - Google Patents

5-HT1F-formidlet inhibering av neurogenisk hjernehinne-ekstravasjon

Info

Publication number
NO971487D0
NO971487D0 NO971487A NO971487A NO971487D0 NO 971487 D0 NO971487 D0 NO 971487D0 NO 971487 A NO971487 A NO 971487A NO 971487 A NO971487 A NO 971487A NO 971487 D0 NO971487 D0 NO 971487D0
Authority
NO
Norway
Prior art keywords
ht1f
mediated inhibition
extravasation
neurogenic
neurogenic meningeal
Prior art date
Application number
NO971487A
Other languages
English (en)
Norwegian (no)
Other versions
NO971487L (no
Inventor
James Edmund Audia
Theresa Branchek
Marlene Lois Cohen
Kirk Willis Johnson
Lee Alan Phebus
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of NO971487L publication Critical patent/NO971487L/no
Publication of NO971487D0 publication Critical patent/NO971487D0/no

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/135Amines having aromatic rings, e.g. ketamine, nortriptyline
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404Indoles, e.g. pindolol
    • A61K31/4045Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4523Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/48Ergoline derivatives, e.g. lysergic acid, ergotamine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/06Antimigraine agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
NO971487A 1994-10-05 1997-04-02 5-HT1F-formidlet inhibering av neurogenisk hjernehinne-ekstravasjon NO971487D0 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/318,330 US5698571A (en) 1994-10-05 1994-10-05 5-HT1F mediated inhibition of neurogenic meningeal extravasation: a method for the treatment of migraine
PCT/US1995/013010 WO1996011006A1 (en) 1994-10-05 1995-10-03 5-ht1f mediated inhibition of neurogenic meningeal extravasation

Publications (2)

Publication Number Publication Date
NO971487L NO971487L (no) 1997-04-02
NO971487D0 true NO971487D0 (no) 1997-04-02

Family

ID=23237717

Family Applications (1)

Application Number Title Priority Date Filing Date
NO971487A NO971487D0 (no) 1994-10-05 1997-04-02 5-HT1F-formidlet inhibering av neurogenisk hjernehinne-ekstravasjon

Country Status (14)

Country Link
US (1) US5698571A (ja)
EP (1) EP0705600A1 (ja)
JP (1) JPH08208516A (ja)
AU (1) AU688168B2 (ja)
CA (1) CA2159767A1 (ja)
CZ (1) CZ93097A3 (ja)
HU (1) HUT77885A (ja)
NO (1) NO971487D0 (ja)
NZ (1) NZ296252A (ja)
RU (1) RU2183457C2 (ja)
TW (1) TW492864B (ja)
UA (1) UA44284C2 (ja)
WO (1) WO1996011006A1 (ja)
ZA (1) ZA958314B (ja)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6406859B1 (en) 1992-01-08 2002-06-18 Synaptic Pharmaceutical Corporation DNA encoding a 5-HT 1F receptor and uses thereof
DE69610793T2 (de) * 1995-06-23 2001-05-03 Eli Lilly And Co., Indianapolis 6-Subsitituierte-1,2,3,4-tetrahydro-9H-Carbazole und 7-substituierte-1OH-Cyclohepta(7,6-B)-Indole
US8022095B2 (en) * 1996-08-16 2011-09-20 Pozen, Inc. Methods of treating headaches using 5-HT agonists in combination with long-acting NSAIDs
US5962473A (en) * 1996-08-16 1999-10-05 Eli Lilly And Company Methods of treating or ameliorating the symptoms of common cold or allergic rhinitis with serotonin 5-HT1F
TR199900430T2 (xx) * 1996-08-28 1999-06-21 Eli Lilly And Company �kameli 1,2,3,4-tetrahidro-2-dibenzofuranaminler ve 2-aminosiklohepta$b] benzofuranlar.
AU4074897A (en) * 1996-09-18 1998-04-14 Eli Lilly And Company A method for the prevention of migraine
GB9706089D0 (en) * 1997-03-24 1997-05-14 Scherer Ltd R P Pharmaceutical composition
US6066092A (en) * 1997-11-06 2000-05-23 Cady; Roger K. Preemptive prophylaxis of migraine device and method
AU4977899A (en) * 1998-07-27 2000-02-21 Eli Lilly And Company Treatment of anxiety disorders
GB9816556D0 (en) * 1998-07-30 1998-09-30 Pfizer Ltd Therapy
US6255334B1 (en) * 1998-10-30 2001-07-03 Pfizer Inc 5HT 1 receptor agonists and metoclopramide for the treatment of migraine
CA2535082C (en) * 2000-11-27 2013-11-19 Terry Cassaday Chair or bed member having data storage
US8329734B2 (en) * 2009-07-27 2012-12-11 Afgin Pharma Llc Topical therapy for migraine
DK1435945T3 (da) * 2001-06-05 2008-12-01 Ronald Aung-Din Topisk migræne terapi
US7482366B2 (en) 2001-12-21 2009-01-27 X-Ceptor Therapeutics, Inc. Modulators of LXR
EP1465869B1 (en) 2001-12-21 2013-05-15 Exelixis Patent Company LLC Modulators of lxr
TWI263497B (en) * 2002-03-29 2006-10-11 Lilly Co Eli Pyridinoylpiperidines as 5-HT1F agonists
ES2380827T3 (es) * 2002-12-26 2012-05-18 Pozen, Inc. Formas de dosificación con múltiples capas que contienen naproxeno y triptanes
US20070065463A1 (en) 2003-06-20 2007-03-22 Ronald Aung-Din Topical therapy for the treatment of migranes, muscle sprains, muscle spasms, spasticity and related conditions
US20060002989A1 (en) * 2004-06-10 2006-01-05 Ahmed Salah U Formulations of sumatriptan for absorption across biological membranes, and methods of making and using the same
JP2008521771A (ja) 2004-11-26 2008-06-26 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ 改良された抗精神病活性および抗不安症活性を有するイソキサゾリン−インドール誘導体
JP2011526889A (ja) 2008-06-30 2011-10-20 アフギン ファーマ,エルエルシー 局所局部的神経作用療法
CN102753171A (zh) 2009-04-02 2012-10-24 科鲁西德制药公司 2,4,6-三氟-n-[6-(1-甲基-哌啶-4-羰基)-吡啶-2-基]-苯甲酰胺的组合物
US8697876B2 (en) 2010-04-02 2014-04-15 Colucid Pharmaceuticals, Inc. Compositions and methods of synthesis of pyridinolypiperidine 5-HT1F agonists
HK1244715A1 (zh) 2015-03-02 2018-08-17 阿福金制药有限责任公司 用大麻素的局部区域神经影响性疗法
US10383816B2 (en) 2015-03-02 2019-08-20 Afgin Pharma, Llc Topical regional neuro-affective therapy with cannabinoid combination products
US20180049994A1 (en) 2016-08-16 2018-02-22 Afgin Pharma, Llc Topical regional neuro-affective therapy with caryophyllene
TWI826514B (zh) * 2018-09-04 2023-12-21 美商美國禮來大藥廠 用於預防偏頭痛之拉米迪坦(lasmiditan)長期夜間投藥
TWI829107B (zh) 2019-07-09 2024-01-11 美商美國禮來大藥廠 大規模製備2,4,6-三氟-n-[6-(1-甲基-哌啶-4-羰基)-吡啶-2-基]-苯甲醯胺半琥珀酸鹽的方法及中間體,以及2,4,6-三氟-n-[6-(1-甲基-哌啶-4-羰基)-吡啶-2-基]-苯甲醯胺醋酸鹽之製備

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL96891A0 (en) * 1990-01-17 1992-03-29 Merck Sharp & Dohme Indole-substituted five-membered heteroaromatic compounds,their preparation and pharmaceutical compositions containing them
US5360735A (en) * 1992-01-08 1994-11-01 Synaptic Pharmaceutical Corporation DNA encoding a human 5-HT1F receptor, vectors, and host cells

Also Published As

Publication number Publication date
NZ296252A (en) 1999-10-28
CZ93097A3 (en) 1997-09-17
ZA958314B (en) 1997-04-03
AU3999695A (en) 1996-05-02
NO971487L (no) 1997-04-02
AU688168B2 (en) 1998-03-05
TW492864B (en) 2002-07-01
HUT77885A (hu) 1998-09-28
WO1996011006A1 (en) 1996-04-18
RU2183457C2 (ru) 2002-06-20
US5698571A (en) 1997-12-16
EP0705600A1 (en) 1996-04-10
CA2159767A1 (en) 1996-04-06
MX9702478A (es) 1997-07-31
UA44284C2 (uk) 2002-02-15
JPH08208516A (ja) 1996-08-13

Similar Documents

Publication Publication Date Title
NO971487D0 (no) 5-HT1F-formidlet inhibering av neurogenisk hjernehinne-ekstravasjon
DE69513175D1 (de) Hydrathemmung
DE69505829D1 (de) Schale-bauteil zum korrosionsschutz von einspritzventilen
NO931947D0 (no) Fremgangsmaate for korrosjonshemming
DE69322141D1 (de) Korrosionsinhibierende Zusammensetzung
FI971635L (fi) Menetelmät neuropeptidiin Y liittyvien tilojen inhiboimiseksi
FI951554A0 (fi) Imidatsolipitoisia farnesyyliproteiinitransferaasi-inhibiittoreita
FI963597A7 (fi) Isoprenyylitransferaasi-inhibiittoreita
NO972930D0 (no) Fibronectin-adhesjonsinhibitorer
FI972160A0 (fi) Matriisimetalloproteaasi-inhibiittorit
FI971784A0 (fi) Apolipoproteiini B-synteesin estäjiä
DK0815348T3 (da) Hydrathæmning
EE9700093A (et) Apolipoproteiin-B sünteesi inhiibitorid
EP0781326A4 (en) THE IRS GENFAMILY
FI971632A7 (fi) 5-lipoksygenaasin inhibiittoreita
FI964781A7 (fi) Uusia elastaasi-inhibiittoreita
DE69433141D1 (de) Zusammensetzungen aus kohleteerschlamm
FI953170A7 (fi) Oligunokleotidit isoprenyyliproteiinitransferaasin ilmentämisen inhibiboimiseksi
ID17424A (id) Penghambat matriks metaloproteasa oleh senyawa-senyawa fenetil tersubstitusi
NO990116D0 (no) Korrosjonsinhibering
NO914123L (no) Fremgangsmaate for korrosjonsbeskyttelse av j-roer
DE69524967D1 (de) Korrosionsinhibierende zusammensetzungen
IS4339A (is) Hömlun ljóssundurliðunar á 3-setnum-2-oxindólum
KR950024188U (ko) 갈치주낚용 도래의 고정구
DE69735249D1 (de) Bindungsinhibition des H-Komplementfaktors